Amgen Inc. (NASDAQ:AMGN) Shares Acquired by McAdam LLC

McAdam LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 5.9% in the fourth quarter, HoldingsChannel reports. The firm owned 856 shares of the medical research company’s stock after acquiring an additional 48 shares during the quarter. McAdam LLC’s holdings in Amgen were worth $223,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Golden State Equity Partners boosted its holdings in Amgen by 2,862.6% in the fourth quarter. Golden State Equity Partners now owns 5,155 shares of the medical research company’s stock valued at $1,344,000 after purchasing an additional 4,981 shares during the period. Osborne Partners Capital Management LLC lifted its holdings in Amgen by 0.4% during the 4th quarter. Osborne Partners Capital Management LLC now owns 12,475 shares of the medical research company’s stock worth $3,251,000 after buying an additional 50 shares during the last quarter. Richardson Financial Services Inc. lifted its holdings in Amgen by 6.8% during the 4th quarter. Richardson Financial Services Inc. now owns 2,004 shares of the medical research company’s stock worth $520,000 after buying an additional 127 shares during the last quarter. Sylvest Advisors LLC purchased a new stake in Amgen during the 4th quarter worth about $744,000. Finally, Tokio Marine Asset Management Co. Ltd. lifted its holdings in Amgen by 2.1% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 15,728 shares of the medical research company’s stock worth $4,099,000 after buying an additional 316 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AMGN. Wolfe Research began coverage on Amgen in a report on Friday, November 15th. They set a “peer perform” rating for the company. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Barclays lifted their price target on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Sanford C. Bernstein began coverage on Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target for the company. Finally, TD Cowen lifted their price target on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $314.00.

Amgen Price Performance

AMGN stock opened at $288.87 on Tuesday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The stock’s fifty day simple moving average is $271.06 and its 200-day simple moving average is $304.11. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock has a market capitalization of $155.28 billion, a price-to-earnings ratio of 36.99, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.30%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.